Safety of Intravenous Thrombolysis in Ischemic Stroke Caused by Left Atrial Myxoma

被引：11

作者：

Acampa, Maurizio ^{[1
]}

Tassi, Rossana ^{[1
]}

Guideri, Francesca ^{[1
]}

Marotta, Giovanna ^{[1
]}

Monti, Lucia ^{[2
]}

Capannini, Gianni ^{[3
]}

Cerase, Alfonso ^{[2
]}

Martini, Giuseppe ^{[1
]}

机构：

[1] Santa Maria Scotte Gen Hosp, Azienda Osped Univ Senese, Dept Emergency, Stroke Unit, Siena, Italy

[2] Santa Maria Scotte Gen Hosp, Azienda Osped Univ Senese, Unit NINT Neuroimaging & Neurointervent, Dept Neurol & Sensorial Sci, Siena, Italy

[3] Santa Maria Scotte Gen Hosp, Azienda Osped Univ Senese, Cardiac Surg Unit, Dept Cardiac & Thorac Surg, Siena, Italy

来源：

CURRENT DRUG SAFETY | 2011年 / 6卷 / 05期

关键词：

Stroke; atrial myxoma; thrombolysis;

D O I：

10.2174/157488611798918665

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Intravenous thrombolytic treatment represents the gold standard for acute ischemic stroke treatment. However there is some concern to perform this treatment in patients with known cardiac myxomas for the risk of haemorragic complications. Here we described a 63-year-old patient with ischemic stroke due to embolization of atrial myxoma and treated with intravenous recombinant tissue plasminogen activator alteplase. The patient did not show improvement after treatment; 25 days later a brain CT showed an asymptomatic small hemorrhagic infarction, probably due to the large size of ischemic lesion. The lack of response might be explained by the embolization of a large tumor fragment. One-year after cardiac surgery clinical follow-up did not reveal new neurological signs nor symptoms. This case report suggests that systemic thrombolysis is a safe procedure also in patient with atrial myxoma. The efficacy of therapy seems to be related to embolus composition.

引用

页码：343 / 345

页数：3

共 12 条

[1] Left atrial myxoma and acute myocardial infarction - A dangerous duo in the thrombolytic agent era [J].